{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T22:24:01Z","timestamp":1750544641860},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.conctc.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T20:56:25Z","timestamp":1466715385000},"page":"58-63","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned from SIGNIFY?"],"prefix":"10.1016","volume":"4","author":[{"given":"Gian Piero","family":"Perna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Vagnarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Battistoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9641","key":"10.1016\/j.conctc.2016.06.003_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Beautiful Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.conctc.2016.06.003_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.conctc.2016.06.003_bib3","first-page":"1104","article-title":"Rest heart rate and life expectancy","volume":"30","author":"Levine","year":"1997","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"9744","key":"10.1016\/j.conctc.2016.06.003_bib4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"M1","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.conctc.2016.06.003_bib5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.conctc.2016.06.003_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","article-title":"Funny channels in the control of cardiac rhythm and mode of action of selective blockers","volume":"53","author":"Di Francesco","year":"2006","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.conctc.2016.06.003_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.conctc.2016.06.003_bib8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.conctc.2016.06.003_bib9","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.conctc.2016.06.003_bib10","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of Ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.conctc.2016.06.003_bib11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) inhibitor Ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.conctc.2016.06.003_bib12","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.conctc.2016.06.003_bib13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.conctc.2016.06.003_bib14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.conctc.2016.06.003_bib15","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"REACH Registry Investigators. B-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"issue":"38","key":"10.1016\/j.conctc.2016.06.003_bib16","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","year":"2013","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.conctc.2016.06.003_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa072771","article-title":"Effect of PCI on quality of life in patients with stable coronary disease","volume":"359","author":"Weintraub","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.conctc.2016.06.003_bib18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease. The COURAGE Trial Research Group","volume":"356","author":"Boden","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.conctc.2016.06.003_bib19","series-title":"Pharmacovigilance Risk Assessment Committee (PRAC) Assessment Report on Ivabradine","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.conctc.2016.06.003_bib20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.conctc.2016.06.003_bib21","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0140-6736(08)60601-7","article-title":"Effect of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial","volume":"371","author":"Devereaux","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.conctc.2016.06.003_bib22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in Type 2 diabetes","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.conctc.2016.06.003_bib23","series-title":"Progress in Clinical Biochemistry and Medicine","article-title":"Drug concentration monitoring","author":"Bottoroff","year":"1987"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865415300247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865415300247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T21:58:59Z","timestamp":1536616739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865415300247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":23,"alternative-id":["S2451865415300247"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2016.06.003","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned from SIGNIFY?","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}